The Clinical Contrast Investigation Of Paclitaxel-eluting Stent Between Polymer-free And Durable Polymer In Ptients With Coronary Heart Disease

Objective:To compare the safety and efficacy of near future and long-term of polymer-free paclitexel-eluting stents (YINYITM) and durable polymer paclitaxel-eluting stent (TAXUSTM) in the treatment of coronary heart disease.Methods:A total of 101 patients with symptomatic coronary heart disease who had implanted with stents between March 2009 to February 2010 at Department of Cardiology of the First Affiliated Hospital of Kunming Medical College were divided into two groups according to types of stents:domestic no polymer paclitaxel drug-coated stents group (YINYITM group, n=62) and durable polymer paclitaxel coating stent group (TAXUSTM group, n=39). Baseline clinical characteristics, angiography characteristics and PCI information between two groups were compared. Clinical follow-up was performed by telephone contact or office visit at 6 and 12 months after PCI. The 6-and 12-months follow-up results by comparing major adverse cardiac event (MACE, cardiac death, nonfatal myocardial infarction and target lesion revascularization), stent thrombosis, restenosis and using of drug were analyzed.Results:There were 140 stents implanted in 101 patients in this study.79 YINYI stents and 61 TAXUS stents were implanted in YINYITM group (62 cases) and TAXUSTM group (39 cases) respectively. Baseline clinical characteristics, lesion location, and length and the number of stents implanted per lesion were equally distributed between two groups (P>0.05). There were not acute instent thrombosis at implanting stent in two groups. All 101 patients were followed up for 12 months after PCI. Clinic follow-up at 6 months after PCI,36 patients (58.06%) underwent coronary angiography (CAG) in the YINYITM group,21 patients (53.84%) underwent CAG in the TAXUSTM group, the rate of instent restenosis (ISR) was 5.56% and 4.76% respectively with no significant statistical difference (P>0.05). The incidence of MACE was 3.23% in the YINYITM group and 2.56% in the TAXUSTM group with no significant statistical difference (P>0.05). There was no stent thrombosis, cardiac death, nonfatal myocardial infarction during followed up after PCI. Clinic follow-up at 12 months after PCI, angina pectoris occurred in 1 patient at 9 months and confirmed instent restenosis, target lesion revascularization in parallel.The incidence of MACE was 4.84% in the YINYITM group and 2.56% in the TAXUSTM group with no significant statistical difference (P>0.05). There was no stent thrombosis, cardiac death, nonfatal myocardial infarction during followed up after PCI. All patients were taking regular dual antiplatelet therapy.Conclusions:Implantation of the domestic no polymer paclitaxel-eluting stents (YINYITM) in patients with coronary heart disease is safe and effective. Incidence of instent restenosis in YINYITM group was higher than that in TAXUSTM group, but no statistically significant difference.